{
    "timestamp": "12/19/2024 3:49:05",
    "title": "A Public Option for Clinical Trials? Lessons from Convalescent Plasma",
    "link_to_resource": "https://doi.org/10.1017/jme.2024.57",
    "creators": [
        "Victor Roy",
        "Joseph S",
        "Reshma Ramachandran"
    ],
    "material_type": [
        "Reading"
    ],
    "education_level": [
        "College / Upper Division (Undergraduates)",
        "Graduate / Professional"
    ],
    "abstract": "The case of clinical trials for convalescent plasma during COVID-19 illustrates important lessons for realizing public sector approaches to biomedical research and development. These lessons, centering on mission, transparency, and spillover effects, can be translated to wider efforts to develop a \"public option\" for clinical trials.",
    "language": [
        "English"
    ],
    "conditions_of_use": "I don't see any of these",
    "primary_user": [
        "Student",
        "Teacher"
    ],
    "subject_areas": [
        "Law",
        "Life Science"
    ],
    "FORRT_clusters": [
        "Open Data and Materials",
        "Academic Life and Culture"
    ],
    "tags": [
        "COVID-19",
        "Plasma",
        "Public sector"
    ]
}